AR061107A1 - Anticuerpos bloqueantes de la funcion de la integrina (alfa)5(beta)1 humanos y humanizados de gran afinidad con inmunogenicidad reducida - Google Patents
Anticuerpos bloqueantes de la funcion de la integrina (alfa)5(beta)1 humanos y humanizados de gran afinidad con inmunogenicidad reducidaInfo
- Publication number
- AR061107A1 AR061107A1 ARP070102226A ARP070102226A AR061107A1 AR 061107 A1 AR061107 A1 AR 061107A1 AR P070102226 A ARP070102226 A AR P070102226A AR P070102226 A ARP070102226 A AR P070102226A AR 061107 A1 AR061107 A1 AR 061107A1
- Authority
- AR
- Argentina
- Prior art keywords
- humanized
- integrin
- human
- antibody
- function
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
- C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Plant Pathology (AREA)
- Communicable Diseases (AREA)
- Physics & Mathematics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
Abstract
Polipéptidos recombinantes humanos o humanizados que se unen a la integrina alfa5beta1 con gran afinidad y bloquean su funcion. Además, se describen aplicaciones de diagnostico y farmacéutico de los polipéptidos Reivindicacion 1: Un anticuerpo humano o humanizado, o un fragmento de union al antígeno del mismo, que se une a la integrina alfa5beta1 con una afinidad <=100 nM y que inhibe la adhesion de las células que expresan integrina alfa5beta1 a su receptor in vitro e in vivo. Reivindicacion 21: El anticuerpo, o fragmento de anticuerpo, de cualquiera de las reivindicaciones 1-17 en la forma de un polipéptido de fusion. Reivindicacion 24: El anticuerpo, o fragmento de anticuerpo, de la reivindicacion 23, en donde el grupo de marcacion detectable se selecciona entre grupos de marcacion radioactivos, NMR, colorantes, enzimas y fluorescentes.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06010779 | 2006-05-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR061107A1 true AR061107A1 (es) | 2008-08-06 |
Family
ID=38659612
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070102226A AR061107A1 (es) | 2006-05-24 | 2007-05-23 | Anticuerpos bloqueantes de la funcion de la integrina (alfa)5(beta)1 humanos y humanizados de gran afinidad con inmunogenicidad reducida |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20090081207A1 (es) |
| EP (1) | EP2032605A2 (es) |
| JP (1) | JP2009537158A (es) |
| KR (1) | KR20090027218A (es) |
| CN (1) | CN101495515A (es) |
| AR (1) | AR061107A1 (es) |
| AU (1) | AU2007253586A1 (es) |
| BR (1) | BRPI0711796A2 (es) |
| CA (1) | CA2652886A1 (es) |
| CL (1) | CL2007001488A1 (es) |
| CR (1) | CR10456A (es) |
| DO (2) | DOP2007000101A (es) |
| EA (1) | EA200802348A1 (es) |
| EC (1) | ECSP088909A (es) |
| MA (1) | MA30425B1 (es) |
| MX (1) | MX2008014910A (es) |
| NO (1) | NO20085362L (es) |
| PE (1) | PE20080100A1 (es) |
| TN (1) | TNSN08469A1 (es) |
| TW (1) | TW200817433A (es) |
| UY (1) | UY30362A1 (es) |
| WO (1) | WO2007134876A2 (es) |
| ZA (1) | ZA200810850B (es) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7723477B2 (en) | 2005-10-31 | 2010-05-25 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth |
| ES2547421T3 (es) | 2005-10-31 | 2015-10-06 | Oncomed Pharmaceuticals, Inc. | Composiciones y métodos para diagnosticar y tratar el cáncer |
| MY159375A (en) | 2006-03-21 | 2016-12-30 | Genentech Inc | Combinatorial therapy |
| US7973138B2 (en) | 2007-09-26 | 2011-07-05 | Genentech, Inc. | Antibodies |
| CA2714071A1 (en) * | 2008-02-05 | 2009-08-13 | Bristol-Myers Squibb Company | Alpha 5 - beta 1 antibodies and their uses |
| NZ592338A (en) | 2008-09-26 | 2012-11-30 | Oncomed Pharm Inc | Frizzled-binding agents and uses thereof |
| AU2009313389A1 (en) * | 2008-11-06 | 2010-05-14 | Alexion Pharmaceuticals, Inc. | Engineered antibodies with reduced immunogenicity and methods of making |
| AU2009331528A1 (en) * | 2008-12-23 | 2011-08-11 | Astrazeneca Ab | Targeted binding agents directed to alpha5beta1 and uses thereof |
| EP2411411B1 (en) | 2009-03-25 | 2016-08-31 | F.Hoffmann-La Roche Ag | Novel anti-alpha5beta1 antibodies and uses thereof |
| GB0918249D0 (en) | 2009-10-19 | 2009-12-02 | Respivert Ltd | Compounds |
| TWI535445B (zh) | 2010-01-12 | 2016-06-01 | 安可美德藥物股份有限公司 | Ｗｎｔ拮抗劑及治療和篩選方法 |
| AU2011235904B2 (en) | 2010-04-01 | 2015-10-08 | Oncomed Pharmaceuticals, Inc. | Frizzled-binding agents and uses thereof |
| EP2933262B1 (en) * | 2010-07-09 | 2018-05-02 | Affibody AB | Polypeptides |
| UY33337A (es) | 2010-10-18 | 2011-10-31 | Respivert Ltd | DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS |
| EP2545905A1 (en) | 2011-07-11 | 2013-01-16 | Britannia Pharmaceuticals Limited | A new therapeutical composition containing apomorphine as active ingredient |
| TWI586378B (zh) | 2012-03-13 | 2017-06-11 | 瑞斯比維特有限公司 | 新穎醫藥調配物 |
| US9266959B2 (en) | 2012-10-23 | 2016-02-23 | Oncomed Pharmaceuticals, Inc. | Methods of treating neuroendocrine tumors using frizzled-binding agents |
| AU2013370467B2 (en) * | 2012-12-26 | 2018-10-04 | Oncosynergy, Inc. | Anti- integrin beta1 antibody compositions and methods of use thereof |
| US9359444B2 (en) | 2013-02-04 | 2016-06-07 | Oncomed Pharmaceuticals Inc. | Methods and monitoring of treatment with a Wnt pathway inhibitor |
| US9168300B2 (en) | 2013-03-14 | 2015-10-27 | Oncomed Pharmaceuticals, Inc. | MET-binding agents and uses thereof |
| KR20180012832A (ko) * | 2015-06-28 | 2018-02-06 | 올제네시스 바이오테라퓨틱스 아이엔씨. | 혈관신생 억제용 융합 단백질 |
| WO2021015336A1 (ko) * | 2019-07-24 | 2021-01-28 | 가톨릭대학교 산학협력단 | αVβ3 인테그린 표적 단일 도메인 항체 |
| US11723955B1 (en) | 2022-05-13 | 2023-08-15 | Allgenesis Biotherapeutics Inc. | VEGFR fusion protein pharmaceutical composition |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6013495A (en) * | 1994-10-21 | 2000-01-11 | The Scripps Research Institute | Methods of use for integrin B1C cell growth inhibitor |
| US6852318B1 (en) * | 1998-05-08 | 2005-02-08 | The Regents Of The University Of California | Methods for detecting and inhibiting angiogenesis |
| US7285268B2 (en) * | 2002-11-26 | 2007-10-23 | Pdl Biopharma, Inc. | Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis |
| US7276589B2 (en) * | 2002-11-26 | 2007-10-02 | Pdl Biopharma, Inc. | Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis |
| KR20110140143A (ko) * | 2002-11-26 | 2011-12-30 | 애보트 바이오테라퓨틱스 코포레이션 | 혈관형성을 조절하는 α5β1 인테그린에 대한 키메라성 및 인간화 항체 |
| EP1755659B1 (en) * | 2004-03-24 | 2011-11-02 | Abbott Biotherapeutics Corp. | Use of anti-alpha5beta1 antibodies to inhibit cancer cell proliferation |
| MY159375A (en) * | 2006-03-21 | 2016-12-30 | Genentech Inc | Combinatorial therapy |
-
2007
- 2007-05-21 WO PCT/EP2007/004648 patent/WO2007134876A2/en active Application Filing
- 2007-05-21 BR BRPI0711796-5A patent/BRPI0711796A2/pt not_active IP Right Cessation
- 2007-05-21 KR KR1020087031278A patent/KR20090027218A/ko not_active Application Discontinuation
- 2007-05-21 AU AU2007253586A patent/AU2007253586A1/en not_active Abandoned
- 2007-05-21 EP EP07725544A patent/EP2032605A2/en not_active Withdrawn
- 2007-05-21 CN CNA2007800265176A patent/CN101495515A/zh active Pending
- 2007-05-21 JP JP2009511419A patent/JP2009537158A/ja active Pending
- 2007-05-21 CA CA002652886A patent/CA2652886A1/en not_active Abandoned
- 2007-05-21 EA EA200802348A patent/EA200802348A1/ru unknown
- 2007-05-21 MX MX2008014910A patent/MX2008014910A/es not_active Application Discontinuation
- 2007-05-22 UY UY30362A patent/UY30362A1/es not_active Application Discontinuation
- 2007-05-22 DO DO2007000101A patent/DOP2007000101A/es unknown
- 2007-05-22 DO DO2007P000101A patent/DOP20070101A/es unknown
- 2007-05-23 US US11/802,573 patent/US20090081207A1/en not_active Abandoned
- 2007-05-23 PE PE2007000634A patent/PE20080100A1/es not_active Application Discontinuation
- 2007-05-23 AR ARP070102226A patent/AR061107A1/es unknown
- 2007-05-24 TW TW096118587A patent/TW200817433A/zh unknown
- 2007-05-24 CL CL2007001488A patent/CL2007001488A1/es unknown
-
2008
- 2008-11-20 TN TNP2008000469A patent/TNSN08469A1/en unknown
- 2008-11-21 MA MA31403A patent/MA30425B1/fr unknown
- 2008-11-24 CR CR10456A patent/CR10456A/es not_active Application Discontinuation
- 2008-11-24 EC EC2008008909A patent/ECSP088909A/es unknown
- 2008-12-22 NO NO20085362A patent/NO20085362L/no not_active Application Discontinuation
- 2008-12-23 ZA ZA200810850A patent/ZA200810850B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MA30425B1 (fr) | 2009-05-04 |
| DOP20070101A (es) | 2007-12-30 |
| TNSN08469A1 (en) | 2010-04-14 |
| ZA200810850B (en) | 2010-05-26 |
| WO2007134876A3 (en) | 2008-03-27 |
| KR20090027218A (ko) | 2009-03-16 |
| MX2008014910A (es) | 2009-01-23 |
| BRPI0711796A2 (pt) | 2011-12-06 |
| ECSP088909A (es) | 2008-12-30 |
| EA200802348A1 (ru) | 2009-08-28 |
| WO2007134876A2 (en) | 2007-11-29 |
| TW200817433A (en) | 2008-04-16 |
| AU2007253586A1 (en) | 2007-11-29 |
| US20090081207A1 (en) | 2009-03-26 |
| EP2032605A2 (en) | 2009-03-11 |
| PE20080100A1 (es) | 2008-04-18 |
| UY30362A1 (es) | 2008-01-02 |
| JP2009537158A (ja) | 2009-10-29 |
| CA2652886A1 (en) | 2007-11-29 |
| WO2007134876A8 (en) | 2009-07-02 |
| NO20085362L (no) | 2009-02-23 |
| DOP2007000101A (es) | 2007-12-31 |
| CL2007001488A1 (es) | 2008-01-04 |
| CN101495515A (zh) | 2009-07-29 |
| CR10456A (es) | 2009-02-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR061107A1 (es) | Anticuerpos bloqueantes de la funcion de la integrina (alfa)5(beta)1 humanos y humanizados de gran afinidad con inmunogenicidad reducida | |
| AR076797A1 (es) | Anticuerpos triespecificos o tetraespecificos | |
| PE20191463A1 (es) | Anticuerpos biespecificos de union especifica pd1 y lag3 | |
| PE20140218A1 (es) | Composicion farmaceutica | |
| ES2525477T3 (es) | Anticuerpos anti-factor D humanizados | |
| UY29770A1 (es) | Polipéptidos y anticuerpos | |
| TR201910213T4 (tr) | Disülfürle stabilize edilmiş çok değerlikli antikorlar. | |
| RS53752B1 (en) | ANTITELO PROTIV ILT7 | |
| DOP2013000045A (es) | Anticuerpos anti-ox40 y metodos de uso de los mismos | |
| AR047729A1 (es) | Anticuerpos terapeuticos que se unen a la apolipoproteina e (apoe) | |
| PE20141787A1 (es) | Composiciones anti-cgrp y uso de las mismas | |
| RS54424B1 (en) | HUMAN ANTIBODIES CONCERNING CXCR4 AND THEIR USES | |
| DE602006021296D1 (de) | Monoklonale antikörper und einzelkettenantikörper fragments gegen das zelloberflächen prostataspezifische membranantigen | |
| AR073538A1 (es) | Anticuerpos multiespecificos que se unen especificamente al receptor del factor de crecimiento epidermico humano 2 (her2) y al factor de crecimiento endotelial vascular (vegf) | |
| DE69417417D1 (de) | Monoklonale antikörper gegen den alpha-pdgf-rezeptor und deren verwendungen | |
| CO6290705A2 (es) | Anticuerpos monoclonales aislados o porciones de union a antigenos, que se unen especificamente a la integrina alfa 5-beta1, y composiciones farmaceuticamente aceptables de los mismos | |
| RS54113B1 (en) | COMPOSITIONS AND PROCEDURES FOR ANTIBODIES ON THE C5 COMPLEMENTARY PROTEIN | |
| RU2011143905A (ru) | ПОЛИСПЕЦИФИЧНЫЕ АНТИТЕЛА, ВКЛЮЧАЮЩИЕ АНТИТЕЛА ПОЛНОЙ ДЛИНЫ И ОДНОЦЕПОЧЕЧНЫЕ ФРАГМЕНТЫ Fab | |
| BRPI1007867B8 (pt) | anticorpo recombinante ou fragmento de ligação ao antígeno do mesmo, composição farmacêutica e kit compreendendo o referido anticorpo, métodos de detecção de antígeno de troponina i em uma amostra de teste e métodos in vitro de diagnóstico de síndrome coronariana aguda ou infarto do miocárdio em um paciente | |
| AR078751A1 (es) | Moleculas de anticuerpo anti-gcc (guanililo ciclasa c) y composiciones y metodos relacionados | |
| UY31433A1 (es) | Nuevos anticuerpos especificos de los peptidos - amiloides y sus usos como agentes de diagnostico o drogas | |
| PE20090368A1 (es) | Anticuerpos anti-igf | |
| EA201270654A1 (ru) | Моноклональные антитела, связывающие b7h6, и их применение | |
| RU2018141360A (ru) | Contorsbody - одноцепочечный связывающий мишень агент | |
| Liang et al. | Allosteric regulation of fibronectin/α5β1 interaction by fibronectin-binding MSCRAMMs |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |